Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.

Miyamoto, Koji; Aiba, Takeshi; Kimura, Hiromi; Hayashi, Hideki; Ohno, Seiko; Yasuoka, Chie; Tanioka, Yoshihito; Tsuchiya, Takeshi; Yoshida, Yoko; Hayashi, Hiroshi; Tsuboi, Ippei; Nakajima, Ikutaro; Ishibashi, Kohei; Okamura, Hideo; Noda, Takashi; Ishihara, Masaharu; Anzai, Toshihisa; Yasuda, Satoshi; Miyamoto, Yoshihiro; Kamakura, Shiro; Kusano, Kengo; Ogawa, Hisao; Horie, Minoru; Shimizu, Wataru

doi:10.1016/j.hrthm.2014.12.009

Record: found
Abstract: found
Article: not found

Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.

Author(s): Koji Miyamoto, Takeshi Aiba, Hiromi Kimura, Hideki Hayashi, Seiko Ohno, Chie Yasuoka, Yoshihito Tanioka, Takeshi Tsuchiya, Yoko Yoshida, Hiroshi Hayashi, Ippei Tsuboi, Ikutaro Nakajima, Kohei Ishibashi, Hideo Okamura, Takashi Noda, Masaharu Ishihara, Toshihisa Anzai, Satoshi Yasuda, Yoshihiro Miyamoto, Shiro Kamakura, Kengo Kusano, Hisao Ogawa, Minoru Horie, Wataru Shimizu

Publication date: 2015-03-01

Journal: Heart Rhythm

Publisher: Elsevier BV

Keywords: Mutation, Andersen-Tawil syndrome, Long QT, Ventricular arrhythmia, Flecainide

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Andersen-Tawil syndrome (ATS) is an autosomal dominant genetic or sporadic disorder characterized by ventricular arrhythmias (VAs), periodic paralyses, and dysmorphic features. The optimal pharmacological treatment of VAs in patients with ATS remains unknown.